Clinical trial of tirzepatide in people with obesity or overweight without diabetes, followed for 72 weeks and published in the NEJM in 2022. It measured mean weight loss of 16.0% with 5 mg, 21.4% with 10 mg and 22.5% with 15 mg, compared with 2.4% on placebo; it also provided 3-year data (week 176) on weight regain.
Institutional endorsement by Clínica Evolution
This entry is for information. Your case requires an individual medical assessment.
We use our own and third-party cookies to make the site work, to measure how it is used and, if you agree, to measure our campaigns. You can accept all, reject all or choose which ones. Cookie policy
Choose which categories you allow. You can change this at any time from “Cookie settings” at the bottom of the page. Cookie policy
They make the site work: language, visual universe, your assessment in progress and this very choice. They cannot be turned off.
Google Analytics (through Google Tag Manager) and Microsoft Clarity: they measure in aggregate how the site is used and help us spot errors.
Meta pixel (Facebook and Instagram): measures how well our campaigns perform.
